仿真软件公司Simulations Plus（股票代码：SLP）在夜盘交易中股价大幅上涨24.32%，引发市场广泛关注。这一显著涨幅主要源于美国食品药品监督管理局（FDA）宣布的一项重大政策变更。
FDA于周四宣布，计划在单克隆抗体疗法及其他药物的研发过程中，逐步取消动物试验的要求。取而代之的是采用与人类相关的方法，包括基于人工智能的毒性计算模型、细胞系以及类器官毒性测试方法。这一政策预计将立即开始实施，标志着制药行业研发流程的重大转变。
作为一家专注于药物开发模拟软件的公司，Simulations Plus有望从这一政策变更中显著受益。该公司的仿真技术和人工智能模型可能在新的药物测试框架中扮演更加重要的角色，从而推动其业务增长。此外，其他相关概念股也出现不同程度上涨，如Recursion Pharmaceuticals（RXRX）涨超18%，Certara（CERT）涨超4%，反映了市场对这一政策变更潜在影响的积极预期。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.